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Abstract: Theauthorsreportontwomultiplemyelomasiblingpairs.Intheabsenceofaknowndisease-specificmarkeronecanonlyspeculate
on an explanation: is it because of inherited errors or is it related to the same environmental exposure, or both? In this study HLA typing 
andmetabolizingenzymepolymorphismstudieshavebeencarriedoutwiththeaimoffindinginheritedsimilaritiesinthesiblingsor
characteristics that might differ from the average population. Sibling pair 1 shared an HLA haplotype. Sibling pair 2 shared only HLA-
B51, DR4, DRw53, DQ3. Sibling 1/1 was GSTT1 / GSTM1 null and GSTP1 Ile105Val; sibling 1/2 was a GSTT1 / GSTM1 heterozygote 
and GSTP1 Ile105Val; sibling 2/1 and 2/2 were GSTT1 heterozygotes and shared GSTM1 null / GSTP1 Ile105Ile. The siblings had identi-
cal light chain or heavy chain secretion, or both.  The similarities found in the inherited factors together with the same environmental 
exposureinthesiblings’first20yearsoflifeimplythatthedevelopmentofthesamediseasecannotbeacoincidence.
        © Versita Warsaw and Springer-Verlag Berlin Heidelberg.
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1. Introduction
It is always an intriguing puzzle when there is a frequent 
occurrence of a non-contagious disease in the same 
family. This is the case in familial multiple myeloma 
(MM) with the involvement of siblings in most instances. 
Multiple myeloma is responsible for one percent of all 
cancer deaths in the western world.  Familial myeloma 
however is a rare entity.  
 In the absence of a disease-specific alteration – like 
that of the bcr/abl gene rearrangement in chronic myeloid 
leukemia – one can only speculate on the reasons for 
such a development. Did it develop as a consequence 
of inherited errors or result from environmental damage 
the siblings were exposed to in their early years living 
together in the same environment, or both? It is of 
the utmost importance therefore to publish as many 
as possible of the cases found all over the world 
including details of their biological characteristics. 
In this spirit herewith the authors present 
two more families with multiple myeloma 
in siblings. 
2. Material and Methods
HLA-A, -B and -C typing was performed by the standard 
NIH micro-lymphocytotoxicity method [1]. HLA-DR and 
-DQ antigens were determined by DNA based PCR-
SSP technique [2]. GSTM1 GSTT1 genotyping was 
performed by multiplex PCR essentially according 
to earlier enzyme polymorphism studies [3]. GSTP1 
Ile105Val genotypes were identified according to the 
method of Ozawa et al. except that Thermoprime Plus 
Cent. Eur. J. Med. • 4(4) • 2009 • 501-505
DOI: 10.2478/s11536-009-0088-4
501
Familial multiple myeloma. Two more families
DNA polymerase (Abgene, Epsom, Surrey, UK) was 
used for catalysing the PCR reaction [4]. Results and 
clinical data are shown in Table 1-3. Genetic testing of 
siblings was carried out with their informed consent.
3. Results
The siblings had identical light chain or heavy chain 
secretion or both and both had been exposed to known 
mutagens in their first 20 years of life (Table 1). Although 
blood group B was present in two of the four persons it 
Siblings gender Age* paraprotein Blood group Karyotype/FISH Environmental exposure
1/1 F 68 IgG kappa B- N/N Passive smoking in childhood
1 / 2 M 66 IgG kappa A+ N/N Passive smoking in childhood
2/1 M 54 Kappa light chain O+ N/N Aromatic paints
2/2 M 48 IgG kappa B+ N/+11 Aromatic paints, benzene
Table 1. Clinical data of the two multiple myeloma sibling pairs.
Age*: age at diagnosis, N: normal
Sibling 1/1  (F)
A B Cw DR DRw DQ
a 2 63 (Bw4) 7 14 52 5
b 1 57 (Bw4) 6 4 53 8
DRB1* DRB3* DRB4* DRB5* DQB1* DPB1*
a 14XX 01-03 05XX
b 04XX 01 03XX
Sibling  1/2  (M)
A B Cw DR DRw DQ
a 2 63 (Bw4) 7 14 52 5
c 33 14 (Bw6) 1
DRB1* DRB3* DRB4* DRB5* DQB1* DPB1*
14XX 01-03 05XX
01XX
Sibling 2/1    (M)          
A B Cw DR DRw DQ
11 51 (Bw4) 6 4 53 3
13 (Bw4) 7 53 2
DRB1* DRB3* DRB4* DRB5* DQB1* DPB1*
04XX 01 03XX
07XX 01 02XX
Sibling 2/2 (M)     
A B Cw DR DRw DQ
1 8 (Bw6) 7 4 53 3
51 (Bw4) 15 51 6
DRB1* DRB3* DRB4* DRB5* DQB1* DPB1*
04XX 01 03XX
15XX 01-02 06XX
Table 2. HLA- RESULTS.
The 1st siblings share a haplotype. The 2nd siblings share only some of the HLA antigens (HLA-B51, DR4, DRw53, DQ3); without family typing it 
is not possible to prove, that those were inherited from the same parent.
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GSTT1 GSTM1 GSTP1
1 / 1 0 0 Ile/Val
1 / 2 1 1 Ile/Val
2 / 1 1 0 Ile/Ile
2 / 2 1 0 Ile/Ile
Sibling 1/1: GSTT1/ GSTM1 null and GSTP1  Ile/Val ;Sibling 1 / 2: 
GSTT1 / GSTM1 heterozygote and GSTP1  Ile/Val; Sibling 2/1 and 
2/2:  GSTT1 heterozygote and shared GSTM1 null / GSTP1 Ile/
Ile. Interestingly Siblings 2/1 and 2/2 had identical polymorphisms 
concerning all the metabolic enzymes tested and siblings 1/1 
and 1 / 2 were identical only in the homozygozity in the GSTP1 
polymorphism. 
Table 3. GST metabolizing enzyme polymorphism results.
has previously been pointed out that is not the case in 
a large cohort of MM patients [5]. Karyotype analysis 
showed only a single alteration (gain of chromosome 
11) in sibling 2/2.
Sibling pair 1 shared a haplotype. Sibling pair 2 
shared only HLA-B51, DR4, DRw53, DQ3 (Table 2). 
Metabolizing enzyme polymorphism results indicated 
that Sibling 1/1 was GSTT1 / GSTM1 null and 
GSTP1 Ile105Val; Sibling 1/2 was a GSTT1 / GSTM1 
heterozygote and GSTP1 Ile105Val; Sibling 2/1 and 2/2 
were GSTT1 heterozygotes and shared GSTM1 null / 
GSTP1 Ile105Ile (Table 3). Both siblings had wild type 
for H63D and C282Y polymorphism of the HFE gene 
(not shown).
4. Discussion
In the process of carcinogenesis environmental 
genotoxic exposures and inherited susceptibility may 
overcome defence mechanisms such as DNA repair 
and tumor suppressor gene activities. Recently it has 
been proposed that diseases developing in the elderly 
evolve because of failure of the ageing protective 
mechanisms rather than because of the accumulation of 
toxic compounds [6,7]. In this study we point on that this 
might be only one possible explanation among many, 
emphasizing the importance of inherited traits and 
environmental exposures endured in early youth.
The sad example of secondary leukemia is evidence 
that cytostatics that form DNA adducts can induce 
prolonged sister chromatid exchange (SCE) induction 
and so contribute to leukemic transformation, in 
contradistinction to those compounds that are negative 
in the so-called SCE test [8]. These findings would 
support the concept of agent-specific carcinogenesis. 
In the following discussion we reflect on the question 
from the point of view of inherited defence mechanisms 
provided by human metabolic enzymes.
The enzymes of the glutathione S-transferase 
system (GST) catalyze the conjugation of compounds of 
carcinogenic potential rendering them less toxic. Genes 
coding for the GST mu l (GSTM1), theta 1 (GSTT1) 
and GSTP1 metabolizing enzymes are polymorphic in 
humans, and in the case of the “null phenotype” this 
preventative activity is absent. Concerning GSTP1 a 
single nucleotide polymorphism (Ile105Val) results in a 
variant enzyme with lower thermal stability and altered 
catalytic activity. However, the literature discussing 
the relationship of enzyme polymorphism and disease 
development is controversial. In cohorts of 58 and of 86 
MM patients there was no difference in the polymorphism 
of these detoxifying enzymes in comparison to the 
average population [9,10]. In contrast, according to 
the study of Lincz et al. there was a higher incidence 
(22 of 68) of GSTT1 null genotype in cases of multiple 
myeloma than in controls (29 of 176) [11]. Others have 
found that alterations in enzyme polymorphisms lead to 
significant differences in drug availability, consequently 
in drug effectiveness and therefore in prognosis [12]. 
The inherited defect in the hemochromatosis gene 
(HFE) causing iron overload confers oxidative stress to 
tissues predisposing them to malignant transformation 
[13-15].  In our present study the two pairs of siblings 
examined were negative for C282Y and H63D 
mutations. This finding is in concordance with earlier 
results indicating that MM patients are less involved in 
this polymorphism than the average population [16,17]. 
What is it then that predisposes families to the 
development of this B-cell clonal disease? And why do 
not all family members acquire the disease? Moreover, is 
there any inherited characteristic known to be associated 
with the development of multiple myeloma at all?
HLA associations were studied to try to answer these 
questions. 
Grobois B. reported on 15 MM families. One pair 
of siblings who had been HLA typed were identical in 
A1, A2, B15, B41 antigens. In another report, the same 
author introduced two brothers who were completely 
identical in A2, B12, BfS, DR4, B27BFS, DR2GLo1 
antigens [18,19]. Engelhardt M. et al. found a high 
incidence of monoclonal B-cell diseases in the siblings 
of patients with MM who were offering themselves as 
allogeneic donors.  The prevalence of monoclonal B-cell 
disease in asymptomatic siblings of myeloma families 
was 29,6%. HLA-A9 was present in 3 out of 5 families 
where all the siblings had monoclonal B-cell disease [20]. 
In a cohort of 125 MM patients, thirty had 39 relatives 
suffering from several tumors and 28 MM patients had 
second primary malignancies as well. A 40-fold tumor 
incidence increase in MM families was found in contrast 
to the average population [5]. 
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There are many other studies presenting examples 
of familial occurrence of hematological malignancies 
[21-23]. 
Studies in unrelated MM have shown significant 
association of Cw2 or B18 alleles to the process [24,25]. 
These data reflect the fact that although there is not 
really a general disease-specific HLA profile for MM, in 
certain cases the similarities or differences in the HLA 
antigens might be important to better the understanding 
of the disease.
5. Conclusions
Similarities found in siblings concerning the GSM1, GST1 
or GSTP1 metabolizing enzyme genes or HLA markers 
are not surprising. In the first twenty years of life, staying 
in the same environment will probably lead to similar 
disease characteristics in siblings. In the development 
of MM, as in the case of other malignancies, the type of 
exposure, the inborn features of metabolism and repair 
mechanisms are equally important factors. From these 
family studies one might emphasize the importance of 
chronic carcinogen exposure endured in early years of 
life in the etiology of a disease manifesting in the elderly. 
In concordance with previous studies we might also 
conclude that the development of MM in siblings is not 
especially more frequent than that of other malignancies 
in the patients’ family, but significantly more than that 
experienced in the average population. The authors 
therefore suggest patient and family screening for 
cancers, emphasizing the importance of early detection 
and prevention by changing lifestyle to avoid genotoxic 
exposure as much as possible. 
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